0001104659-21-110763.txt : 20210830 0001104659-21-110763.hdr.sgml : 20210830 20210830090855 ACCESSION NUMBER: 0001104659-21-110763 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210827 FILED AS OF DATE: 20210830 DATE AS OF CHANGE: 20210830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36225 FILM NUMBER: 211221235 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kindred Biosciences, Inc. CENTRAL INDEX KEY: 0001561743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461160142 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1555 BAYSHORE HIGHWAY, SUITE 200 CITY: BURLINGAME STATE: CA ZIP: 94010 BUSINESS PHONE: 650-701-7901 MAIL ADDRESS: STREET 1: 1555 BAYSHORE HIGHWAY, SUITE 200 CITY: BURLINGAME STATE: CA ZIP: 94010 4 1 tm2126057-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-08-27 1 0001561743 Kindred Biosciences, Inc. KIN 0001739104 Elanco Animal Health Inc 2500 INNOVATION WAY GREENFIELD IN 46140 0 0 1 0 Common Stock, par value $0.0001 2021-08-27 4 P 0 45508938 9.25 A 10000 D Pursuant to the Agreement and Plan of Merger, dated as of June 15, 2021 and as amended on June 30, 2021, by and among Elanco Animal Health Incorporated, Knight Merger Sub, Inc., a wholly owned subsidiary of Elanco Animal Health Incorporated ("Merger Sub"), and Kindred Biosciences, Inc. ("KindredBio"), Merger Sub merged with and into KindredBio (the "Merger") on August 27, 2021. Upon completion of the Merger, each share of common stock of KindredBio that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation. Consequently, upon the consummation of the Merger on August 27, 2021, Elanco became the owner of 10,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. /s/ Todd Young Todd Young as Executive Vice President and Chief Financial Officer of Elanco Animal Health Incorporated 2021-08-30